Baltimore, MD -- (SBWIRE) -- 09/24/2019 -- Gershon, Willoughby, & Getz, LLC is booking cases with those affected by prescription drug errors. Those who have been seriously harmed, hospitalized, or experienced the death of a loved one by overdose due to a prescription drug error should immediately contact the leading medical malpractice and birth defect attorneys in Baltimore at Gershon, Willoughby, & Getz, LLC.
Gershon, Willoughby, & Getz, LLC would like to inform the public about the dangers of prescription drug errors. Whenever a patient is administered anything other than the medication prescribed to him or her, he or she is a victim of medical malpractice. Prescription drug errors include administering the wrong drug, administering the wrong dosage of the right drug, administering a drug the patient is allergic to, administering a drug that dangerously interacts with another medication, mislabeling medications, and the failure to warn patients of serious side effects. Pharmacies across the nation have contributed to this problem as a result of a pharmacist's negligence.
Though prescription drug errors can be avoided through the conscious training and supervising of new staff, clear and direct communication between doctors and pharmacies, ample pharmacy staffing to reduce workload stress, and patient counseling, the numbers of families affected by this issue is on the rise each year. To learn more about these medical malpractice, birth injury, and cerebral palsy lawyer in Baltimore, MD, and what they can do for those affected by prescription drug errors, please visit https://www.cerebralpalsylawdoctor.com/.
About Gershon, Willoughby, & Getz, LLC
Gershon, Willoughby, & Getz is a nationally recognized medical malpractice and cerebral palsy law firm, which includes doctor-lawyers who represent birth injured children in Maryland, the District of Columbia and throughout the United States on a pro hoc vice basis (with permission of the court).
To learn more, visit their website at https://www.cerebralpalsylawdoctor.com/.
For more information on this press release visit:
Media Relations Contact
Email: Click to Email John Broskey